These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24901552)

  • 61. The new patent regime and disease priorities in India.
    Gupta I; Guin P; Trivedi M
    Glob Public Health; 2013; 8(1):37-54. PubMed ID: 22845021
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Data sharing: Access all areas.
    Owens B
    Nature; 2016 May; 533(7602):S71-2. PubMed ID: 27167398
    [No Abstract]   [Full Text] [Related]  

  • 63. The position of intellectual property rights in drug discovery and development from natural products.
    Boyd MR
    J Ethnopharmacol; 1996 Apr; 51(1-3):17-25; discussion 25-7. PubMed ID: 9213613
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Compound screening: Fresh hunting ground.
    McGilvray A
    Nature; 2016 May; 533(7602):S65-7. PubMed ID: 27167395
    [No Abstract]   [Full Text] [Related]  

  • 65. Patent portfolio management: literature review and a proposed model.
    Conegundes De Jesus CK; Salerno MS
    Expert Opin Ther Pat; 2018 Jun; 28(6):505-516. PubMed ID: 29718747
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Auctioning the cure.
    Willyard C
    Nat Med; 2011 May; 17(5):528-30. PubMed ID: 21546960
    [No Abstract]   [Full Text] [Related]  

  • 67. Introduction: Access to life-saving medicines and intellectual property rights.
    Schroeder D
    Camb Q Healthc Ethics; 2011 Apr; 20(2):277-8. PubMed ID: 21435302
    [No Abstract]   [Full Text] [Related]  

  • 68. Herbal drug patenting in India: IP potential.
    Sahoo N; Manchikanti P; Dey SH
    J Ethnopharmacol; 2011 Sep; 137(1):289-97. PubMed ID: 21640810
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Wild-card patent extensions as a means to incentivize research and development of antibiotics.
    Sonderholm J
    J Law Med Ethics; 2009; 37(2):240-6. PubMed ID: 19493069
    [TBL] [Abstract][Full Text] [Related]  

  • 70. TRIPS: whose interests are being served?
    Kamal M; Bailey M
    Lancet; 2003 Jul; 362(9380):260. PubMed ID: 12892952
    [No Abstract]   [Full Text] [Related]  

  • 71. Incentive to be inventive.
    Nat Rev Drug Discov; 2005 Jul; 4(7):523. PubMed ID: 16060056
    [No Abstract]   [Full Text] [Related]  

  • 72. Introduction: pharmaceutical innovation: law & the public's health.
    Outterson K
    J Law Med Ethics; 2009; 37(2):173-5. PubMed ID: 19493064
    [No Abstract]   [Full Text] [Related]  

  • 73. A consideration of the patentability of enantiomers in the pharmaceutical industry in the United States.
    Miller CP; Ullrich JW
    Chirality; 2008 Jun; 20(6):762-70. PubMed ID: 18200591
    [TBL] [Abstract][Full Text] [Related]  

  • 74. China tightens IP protection, but concerns linger.
    Jia H
    Nat Biotechnol; 2009 Sep; 27(9):787-8. PubMed ID: 19741619
    [No Abstract]   [Full Text] [Related]  

  • 75. Potential effects of increased openness in pharma: the original knowledge behind new drugs.
    Bignami F; Mattsson P
    Drug Discov Today; 2019 Oct; 24(10):1957-1962. PubMed ID: 31254489
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Incentives for drug development--the curious case of colchicine.
    Kesselheim AS; Solomon DH
    N Engl J Med; 2010 Jun; 362(22):2045-7. PubMed ID: 20393164
    [No Abstract]   [Full Text] [Related]  

  • 77. Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand.
    Supakankunti S; Janjaroen WS; Tangphao O; Ratanawijitrasin S; Kraipornsak P; Pradithavanij P
    Bull World Health Organ; 2001; 79(5):461-70. PubMed ID: 11417042
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Medicine patent pool--pharma philanthropy or PR?
    De Luca C
    Expert Opin Ther Pat; 2015; 25(11):1223-7. PubMed ID: 26291460
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.
    Woosley RL; Myers RT; Goodsaid F
    Clin Pharmacol Ther; 2010 May; 87(5):530-3. PubMed ID: 20407457
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Patent implications in the pharmaceutical industry: Are static high prices leading to dynamic innovations?
    Pandey E; Paul SB
    Int J Risk Saf Med; 2019; 30(3):179-192. PubMed ID: 31450515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.